IL17A and inflammatory bowel disease: Traditionally, the most commonly utilized models in IBD involve murine models, including IL10-pathway knockouts, the T-cell transfer model, DSS treatment and, more recently, the abcb1a knockout (mdr1a−/−), which accurately predicted human responses to blockade of IL12/23 and IL17 as being beneficial and harmful, respectively (Keubler et al., 2015; Ostanin et al., 2009; Chassaing et al., 2014; Wilk et al., 2005).